744 related articles for article (PubMed ID: 28454499)
21. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
[TBL] [Abstract][Full Text] [Related]
22. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value.
Song DK; Oh JY; Lee H; Sung YA
Korean J Intern Med; 2017 Jul; 32(4):690-698. PubMed ID: 27899014
[TBL] [Abstract][Full Text] [Related]
23. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS.
Rudnicka E; Kunicki M; Calik-Ksepka A; Suchta K; Duszewska A; Smolarczyk K; Smolarczyk R
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830389
[TBL] [Abstract][Full Text] [Related]
24. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
Bell RJ; Islam RM; Skiba MA; Herbert D; Martinez Garcia A; Davis SR
Hum Reprod; 2021 Dec; 37(1):109-118. PubMed ID: 34741176
[TBL] [Abstract][Full Text] [Related]
25. Loss of anti-Müllerian hormone (AMH) immunoactivity due to a homozygous AMH gene variant rs10417628 in a woman with classical polycystic ovary syndrome (PCOS).
Hoyos LR; Visser JA; McLuskey A; Chazenbalk GD; Grogan TR; Dumesic DA
Hum Reprod; 2020 Oct; 35(10):2294-2302. PubMed ID: 32918081
[TBL] [Abstract][Full Text] [Related]
26. Antimüllerian hormone to determine polycystic ovarian morphology.
Dietz de Loos A; Hund M; Buck K; Meun C; Sillman J; Laven JSE
Fertil Steril; 2021 Oct; 116(4):1149-1157. PubMed ID: 34579824
[TBL] [Abstract][Full Text] [Related]
27. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
[TBL] [Abstract][Full Text] [Related]
28. Anti-Müllerian hormone and polycystic ovary syndrome.
Bhide P; Homburg R
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():38-45. PubMed ID: 27103234
[TBL] [Abstract][Full Text] [Related]
29. Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate.
Leonhardt H; Hellström M; Gull B; Lind AK; Nilsson L; Janson PO; Stener-Victorin E
Fertil Steril; 2014 Jun; 101(6):1747-56.e1-3. PubMed ID: 24661732
[TBL] [Abstract][Full Text] [Related]
30. DIAGNOSTIC VALUE OF ANTI-MÜLLERIAN HORMONE AS A BIOMARKER FOR POLYCYSTIC OVARY SYNDROME: A META-ANALYSIS UPDATE.
Zhao Y; Zhao Y; Wang C; Liang Z; Liu X
Endocr Pract; 2019 Oct; 25(10):1056-1066. PubMed ID: 31414908
[No Abstract] [Full Text] [Related]
31. Revisiting the serum level of anti-Müllerian hormone in patients with functional hypothalamic anovulation.
Makolle S; Catteau-Jonard S; Robin G; Dewailly D
Hum Reprod; 2021 Mar; 36(4):1043-1051. PubMed ID: 33580689
[TBL] [Abstract][Full Text] [Related]
32. Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome.
Bradbury RA; Lee P; Smith HC
Aust N Z J Obstet Gynaecol; 2017 Oct; 57(5):552-557. PubMed ID: 28597496
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology.
Vural F; Vural B; Kardaş E; Ertürk Coşkun AD; Yildirim İ
Arch Gynecol Obstet; 2023 Apr; 307(4):1083-1090. PubMed ID: 36565362
[TBL] [Abstract][Full Text] [Related]
34. Anti-Müllerian hormone reflects the severity of polycystic ovary syndrome.
Jacob SL; Field HP; Calder N; Picton HM; Balen AH; Barth JH
Clin Endocrinol (Oxf); 2017 Mar; 86(3):395-400. PubMed ID: 27805276
[TBL] [Abstract][Full Text] [Related]
35. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome.
Nardo LG; Yates AP; Roberts SA; Pemberton P; Laing I
Hum Reprod; 2009 Nov; 24(11):2917-23. PubMed ID: 19617605
[TBL] [Abstract][Full Text] [Related]
36. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic criteria for PCOS: Is there a need for a rethink?
Dewailly D
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():5-11. PubMed ID: 27151631
[TBL] [Abstract][Full Text] [Related]
38. The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome.
Qi X; Pang Y; Qiao J
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():82-7. PubMed ID: 26914398
[TBL] [Abstract][Full Text] [Related]
39. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.
Dewailly D; Robin G; Peigne M; Decanter C; Pigny P; Catteau-Jonard S
Hum Reprod Update; 2016 Nov; 22(6):709-724. PubMed ID: 27566840
[TBL] [Abstract][Full Text] [Related]
40. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
